Betamethasone

What it is

Betamethasone is a synthetic fluorinated corticosteroid, a laboratory-modified relative of cortisol. It is sold as several different salts and esters, each made for a different route: an injectable acetate/sodium-phosphate suspension for intramuscular, intra-articular and intralesional use, and dipropionate or valerate creams, ointments, lotions and scalp preparations for the skin. It is a high-potency topical steroid and a long-acting systemic one, broken down by the liver enzyme CYP3A4.

What the research says

What is known depends entirely on the route and the condition. The strongest evidence is for a single course injected into a pregnant woman expected to deliver preterm: Cochrane rates it high certainty that this cuts perinatal death, neonatal death and respiratory distress syndrome, with absolute reductions of roughly 2 to 4 percentage points. The same intervention raised neonatal low blood sugar from 15% to 24% in the late-preterm trial, and a programme rolling it out in low-resource settings increased overall neonatal deaths and maternal infection. On the skin, high-potency topical steroids clear psoriasis plaques better than vitamin D analogues, at the cost of skin thinning, stretch marks and, with large amounts, suppression of the body's own cortisol production. For most of the dozens of conditions listed on the injection label there is no randomised outcome trial of betamethasone specifically.

Evidence grade: Well established.

How it works

Drug class: Synthetic long-acting fluorinated glucocorticoid (corticosteroid); topical esters are high-potency class

Betamethasone enters cells and binds the glucocorticoid receptor, which then switches many genes on or off. The practical result is a broad shutdown of inflammation - fewer inflammatory signalling molecules, fewer white cells recruited into tissue - plus the metabolic effects of cortisol, which is why large or repeated doses raise blood pressure, hold on to salt and water, waste potassium, increase calcium loss and suppress the body's own cortisol production. (Source 1)

What it is used for

• Cochrane rates it high certainty that a single antenatal corticosteroid course reduces perinatal death, neonatal death and respiratory distress syndrome, with absolute reductions of about 2.3%, 2.6% and 4.3%. Note that antenatal use does not appear among the indications on the US Celestone Soluspan label, which lists allergic, dermatologic, endocrine, rheumatic and other conditions - this is an off-label but guideline-endorsed use in the United States, and labelling differs by country. Evidence: established. (Source 2)
• The ALPS trial found the composite respiratory outcome in 11.6% on betamethasone versus 14.4% on placebo (RR 0.80), an absolute reduction of 2.8 percentage points, but neonatal low blood sugar rose from 15.0% to 24.0%. A follow-up of the same children at a median age of 7 years found no difference in cognitive ability. Evidence: established. (Source 3)
• In a Cochrane review of 59 trials in scalp psoriasis, high- and very-high-potency topical steroids cleared lesions better than vitamin D analogues (RR 1.82, number needed to treat 8) and caused fewer withdrawals for side effects; the combination with calcipotriol added only a small further benefit. Most of the evidence is short-term, under six months. Evidence: established. (Source 4)
• The injectable suspension is approved for short-term intra-articular use and is widely given, but we found no randomised outcome trial of betamethasone specifically for knee osteoarthritis or bursitis in this search; the best-quality study we located measured only its effect on the adrenal axis. Evidence: limited. (Source 5)
• Small single-centre series report success rates around 64 to 70% with an 8-week course of 0.1% betamethasone valerate, with no detected systemic cortisol effect in a later randomised trial; there is no placebo-controlled trial of adequate size in this search. Evidence: limited. (Source 6)
• A randomised trial followed children to 6 to 8 years and found repeat doses produced neither benefit nor harm on survival free of neurosensory disability (78.3% versus 77.3%), so repeat courses rest on their short-term neonatal effects rather than on long-term gain. Evidence: disputed. (Source 7)
• The label states plainly that effectiveness by this route has not been established and that corticosteroids are not approved for it, and records serious neurological events including deaths. Evidence: not-supported. (Source 8)

Interactions

• Strong CYP3A4 inhibitors, ketoconazole in particular (pharmacokinetic study): Ketoconazole slows the breakdown of corticosteroids by up to 60%, so more betamethasone stays in the body and systemic side effects become more likely. Other strong inhibitors such as itraconazole, clarithromycin and ritonavir do the same. (Source 9)
• Grapefruit and grapefruit juice (theoretical): Grapefruit inhibits CYP3A4, the enzyme that clears betamethasone, so it would in theory raise exposure. We found no study measuring this for betamethasone, so the link is inferred from the metabolic pathway. (Source 9)
• St John's wort (Hypericum perforatum) (theoretical): St John's wort induces CYP3A4, so it would be expected to speed betamethasone's clearance and weaken its effect. No betamethasone-specific study was found; this is inferred from the pathway. (Source 9)
• Potassium-depleting drugs - loop and thiazide diuretics, amphotericin B (case reports): Corticosteroids make the kidney excrete potassium, so combining them with a diuretic or amphotericin B can drop potassium far enough to matter. Cases of heart enlargement and heart failure have been reported with amphotericin B plus a corticosteroid. (Source 10)
• Potassium and dietary salt (label): Average and large corticosteroid doses raise blood pressure, hold on to salt and water and push potassium out, so salt restriction and potassium replacement are sometimes needed. This is a nutrient consequence of the drug rather than an interaction that changes drug levels. (Source 1)
• Calcium and vitamin D (label): All corticosteroids increase calcium loss in the urine, which is part of why long courses are linked to bone loss; this is the reason calcium and vitamin D are commonly given alongside, though the label states the effect rather than endorsing a supplement. (Source 1)
• Aspirin and other non-steroidal anti-inflammatory drugs (label): Taken together with a corticosteroid, aspirin or an NSAID raises the risk of stomach and bowel side effects including ulceration and bleeding. Corticosteroids may also increase how fast salicylates are cleared. (Source 11)
• Alcohol (theoretical): We found no documented pharmacokinetic interaction between alcohol and betamethasone. The concern that is documented is additive stomach irritation: the label records that corticosteroids plus aspirin or an NSAID raise gastrointestinal risk, and alcohol is an independent gastric irritant, so this is a theoretical additive risk rather than a measured interaction. The only alcohol the label discusses directly is benzyl alcohol used as a preservative, which has been linked to a fatal gasping syndrome in premature and low-birthweight infants. (Source 12)
• Warfarin (case reports): Corticosteroids usually blunt warfarin's effect, though reports conflict, so clotting tests need checking more often when a corticosteroid is started or stopped. (Source 13)
• Live and live attenuated vaccines (label): At immunosuppressive doses, corticosteroids make live vaccines unsafe and blunt the response to killed ones. Replacement-dose steroid therapy, as in Addison's disease, is not a barrier to immunisation. (Source 14)

Stopping it

• After topical use, the body's own cortisol production usually recovers quickly and completely once the steroid is stopped, but withdrawal symptoms do occasionally appear and occasionally need systemic steroid cover. (Source 15)
• If testing shows the adrenal axis is suppressed during topical treatment, the documented options are to withdraw the drug, use it less often, or switch to a weaker steroid rather than stop abruptly and hope. (Source 15)
• For the antenatal use, stopping is not the question - it is a single two-dose course, and the randomised evidence on continuing with weekly repeat courses showed no long-term benefit or harm by mid-childhood, so repeat courses are not justified by long-term outcomes. (Source 7)
• Raised pressure inside the skull with swelling of the optic disc is listed as usually following discontinuation of corticosteroid treatment, so the period after stopping a systemic course is not risk-free. (Source 16)

What goes wrong

Late preterm betamethasone raised the rate of newborn low blood sugar from 15% to 24%. (Source 3)

• Randomized trial, High certainty.
• Size: 2,827 infants.
• Who: late preterm infants in the ALPS trial.
• How long: neonatal period.
• Result: neonatal hypoglycaemia 24.0% versus 15.0%, RR 1.60 (95% CI 1.37-1.87), P<0.001 - an absolute increase of 9 percentage points, about one extra case for every 11 women treated.
• Funding: NHLBI and NICHD (public funding)

Neonatal hypoglycemia was more common in the betamethasone group than in the placebo group (24.0% vs. 15.0%; relative risk, 1.60; 95% CI, 1.37 to 1.87; P<0.001).

Scaling up antenatal corticosteroids in low-resource settings was followed by more neonatal deaths across the whole population (not just the low-birthweight group) and more suspected maternal infection. (Source 17)

• Randomized trial, Moderate certainty.
• Size: 99,742 women across 101 clusters.
• Who: all women delivering in the intervention and control clusters, not only those at risk of preterm birth.
• How long: 18 months.
• Result: population 28-day neonatal mortality 27.4 versus 23.9 per 1000 livebirths, RR 1.12 (95% CI 1.02-1.22, p=0.0127), an excess of about 3.5 neonatal deaths per 1000 women exposed; suspected maternal infection OR 1.45 (1.33-1.58) overall and OR 1.67 (1.33-2.09) in the low-birthweight group.
• Funding: NICHD (public funding)

Among the whole population, 28-day neonatal mortality was 27·4 per 1000 livebirths for the intervention group and 23·9 per 1000 livebirths for the control group (RR 1·12, 1·02-1·22, p=0·0127) and suspected maternal infection was reported in 1207 (3%) of 48,219 women in the intervention group and 867 (2%) of 51,523 in the control group (OR 1·45, 1·33-1·58, p<0·0001).

In a national cohort, children exposed to antenatal corticosteroids had a higher rate of mental and behavioural disorders, including when born at term and when compared with their own unexposed siblings. (Source 18)

• Cohort study, Low certainty.
• Size: 670,097 singleton children, 14,868 of them exposed; 4,128 term sibling pairs discordant for exposure.
• Who: all singleton live births in Finland 2006-2017 surviving to 1 year.
• How long: median follow-up 5.8 years.
• Result: any mental or behavioural disorder 12.01% versus 6.45% overall, absolute difference 5.56% (95% CI 5.04-6.19), adjusted HR 1.33 (1.26-1.41); in term-born children 8.89% versus 6.31%, HR 1.47; within discordant sibling pairs 6.56% versus 4.17%, HR 1.38; in preterm-born children the hazard ratio was not significant (HR 1.00, 0.92-1.09)
• Funding: not stated in the abstract; registry-based academic study.

Treatment exposure, compared with nonexposure, was significantly associated with higher risk of any mental and behavioral disorder in the entire cohort of children (12.01% vs 6.45%; absolute difference, 5.56%

Topical betamethasone dipropionate causes local skin damage including skin thinning and stretch marks, and can suppress the body's own cortisol production. (Source 19)

• Official position, Low certainty.
• Size: not quantified on the label; reactions described as reported infrequently when used as directed.
• Who: people using betamethasone dipropionate cream, ointment or lotion.
• How long: not stated; risk rises with potency, large surface area, long use and occlusion.
• Result: burning, itching, irritation, dryness, folliculitis, excess hair growth, acne-like eruptions, loss of pigment, perioral dermatitis, allergic contact dermatitis, skin maceration, secondary infection, skin atrophy, striae and miliaria; reversible HPA axis suppression, Cushing's syndrome, high blood sugar and glucose in the urine from systemic absorption.
• Funding: manufacturer document (regulatory label)

These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infections, skin atrophy, striae and miliaria.

Children absorb proportionally more topical steroid than adults and adrenal suppression in a child can show up as slowed growth. (Source 20)

• Official position, Low certainty.
• Size: not quantified on the label.
• Who: children treated with topical corticosteroids.
• How long: not stated.
• Result: HPA axis suppression, Cushing's syndrome and raised intracranial pressure reported in children; signs include linear growth retardation, delayed weight gain, low plasma cortisol and no response to ACTH stimulation; intracranial hypertension can present as bulging fontanelles, headaches and papilloedema.
• Funding: manufacturer document (regulatory label)

Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation.

About 5% of people with extensive psoriasis treated with a calcipotriene plus betamethasone dipropionate suspension showed adrenal suppression on testing. (Source 21)

• Randomized trial, Very low certainty.
• Size: 43 subjects.
• Who: adults with psoriasis vulgaris covering 15-30% of body surface area.
• How long: 8 weeks, once daily, open label with no control group.
• Result: 2 of 43 (4.7%) had an abnormal ACTH stimulation result at week 4 (serum cortisol 18 mcg/dL or less); both normalised 4 weeks after stopping; no clinically relevant changes in serum or urinary calcium.
• Funding: not stated in the abstract; the product is a manufacturer's two-compound formulation and the design is an open, non-controlled manufacturer-type safety study.

Two (4.7%) subjects showed signs of adrenal suppression based on the ACTH stimulation test results at week 4

Skin thinning from topical corticosteroids is a real but badly measured harm - trials of these drugs have reported it poorly and there is no standardised way to assess it. (Source 22)

• Expert review, not systematic, Very low certainty.
• Size: 60 articles retrieved from PubMed, EMBASE and Cochrane Central, 1965 to May 2013.
• Who: trials in healthy skin and trials of topical corticosteroids reporting atrophy as a safety endpoint.
• How long: review notes atrophy arises from chronic rather than acute use.
• Result: no pooled estimate given; epidermal thickness appeared more sensitive than whole-skin thickness for detecting early atrophy, and measurement still requires standardisation.
• Funding: not stated.

Skin atrophy is an adverse effect of topical corticosteroids (TCs) which, as an established non-life-threatening effect, has been poorly reported by trials involving these drugs.

Corticosteroid injection into the epidural space has caused deaths and permanent neurological injury, and the label states effectiveness by this route is not established. (Source 8)

• Official position, Certainty not rated.
• Size: spontaneous reports, not quantified.
• Who: patients given epidural corticosteroid injections.
• How long: not applicable.
• Result: spinal cord infarction, paraplegia, quadriplegia, cortical blindness and stroke, reported with and without fluoroscopy.
• Funding: manufacturer document (regulatory label)

Serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids.

Corticosteroids by any route can slow a child's growth, and this has been seen at low doses without any laboratory sign of adrenal suppression. (Source 23)

• Official position, Low certainty.
• Size: not quantified on the label.
• Who: paediatric patients treated with corticosteroids by any route.
• How long: prolonged treatment.
• Result: decrease in growth velocity; the label calls growth velocity a more sensitive indicator of systemic corticosteroid exposure than common tests of HPA axis function.
• Funding: manufacturer document (regulatory label)

This negative impact of corticosteroids on growth has been observed at low systemic doses and in the absence of laboratory evidence of HPA axis suppression

What the evidence supports

A single antenatal corticosteroid course reduces perinatal death, neonatal death and respiratory distress syndrome, with absolute reductions of about 2 to 4 percentage points. (Source 2)

• Systematic review, High certainty.
• Size: 27 studies, 11,272 randomised women and 11,925 neonates from 20 countries; 9,833 infants in the perinatal death analysis.
• Who: women at risk of preterm birth before 37 weeks, singleton and multiple pregnancies, 10 trials in lower- or middle-resource settings.
• How long: single course before delivery, with neonatal and childhood follow-up.
• Result: perinatal death RR 0.85 (95% CI 0.77-0.93), 2.3% fewer (1.1% to 3.6% fewer); neonatal death RR 0.78 (0.70-0.87), 2.6% fewer; RDS RR 0.71 (0.65-0.78), 4.3% fewer; intraventricular haemorrhage RR 0.58 (0.45-0.75), 1.4% fewer, moderate certainty.
• Funding: Cochrane review, independent; six previously included trials were removed for failing trustworthiness criteria.

perinatal death (risk ratio (RR) 0.85, 95% confidence interval (CI) 0.77 to 0.93; 9833 infants; 14 studies; high-certainty evidence; 2.3% fewer

Betamethasone given at 34 to 36 weeks reduced a composite of neonatal respiratory treatment, stillbirth and early neonatal death. (Source 3)

• Randomized trial, High certainty.
• Size: 2,827 infants (1,427 betamethasone, 1,400 placebo)
• Who: women with a singleton pregnancy at 34 weeks 0 days to 36 weeks 5 days at high risk of late preterm delivery.
• How long: two injections 24 hours apart; outcomes in the first 72 hours.
• Result: primary outcome 165/1427 (11.6%) versus 202/1400 (14.4%), RR 0.80 (95% CI 0.66-0.97), P=0.02 - an absolute difference of 2.8 percentage points, about 36 women treated per event avoided.
• Funding: National Heart, Lung, and Blood Institute and NICHD (public funding)

The primary outcome occurred in 165 of 1427 infants (11.6%) in the betamethasone group and 202 of 1400 (14.4%) in the placebo group (relative risk in the betamethasone group, 0.80; 95% confidence interval [CI], 0.66 to 0.97; P=0.02).

High-potency topical steroids, the class betamethasone dipropionate belongs to, clear scalp psoriasis better than vitamin D analogues with a number needed to treat of 8. (Source 4)

• Systematic review, Moderate certainty.
• Size: 59 randomised trials, 11,561 participants; 2,180 participants in the clearance comparison.
• Who: people of all ages with scalp psoriasis.
• How long: mostly under six months; only one trial ran 12 months.
• Result: clearance RR 1.82 (95% CI 1.52-2.18), NNTB 8 (7 to 11), moderate quality; steroids caused fewer withdrawals for adverse events than vitamin D (RR 0.22, 0.11-0.42); the two-compound combination added only a small benefit over steroid alone (RR 1.22, NNTB 17)
• Funding: thirty of the 59 included studies were conducted or sponsored by the manufacturer of the study medication.

steroids were better than vitamin D (RR 1.82; 95% CI 1.52 to 2.18; four studies, 2180 participants, NNTB = 8; 95% CI 7 to 11; moderate quality evidence)

Topical 0.1% betamethasone valerate resolved phimosis in about two-thirds of boys in an uncontrolled series. (Source 6)

• Case series, Very low certainty.
• Size: 36 boys treated topically out of 55 seen.
• Who: boys under 10 years with phimosis at one department.
• How long: 8-week course, assessed at 3 and 8.3 months.
• Result: success 69.4% at 3 months and 63.9% at 8.3 months; pretreatment phimosis grade did not predict success (P > .05); no side effects reported.
• Funding: not stated.

The success rate for the topical steroid cream was 69.4% and 63.9% at 3 and 8.3 months, respectively.

A single 6 mg betamethasone injection into the knee did not significantly suppress the adrenal axis in a small controlled study, though one of twenty patients met the criterion. (Source 5)

• Case-control study, Very low certainty.
• Size: 40 patients, 20 per group.
• Who: adults with osteoarthritic knee pain not responding to medical and physical therapy, compared with patients given intra-articular hyaluronate.
• How long: ACTH stimulation tests before injection and at 1, 2, 3, 4 and 8 weeks.
• Result: 1 of 20 in the betamethasone group met criteria for secondary adrenal insufficiency at 3 weeks versus 0 of 20 controls (P > 0.9999); his 30-minute cortisol was 17 mcg/dL with a rise of 3 mcg/dL.
• Funding: not stated.

One patient only from group 1 (the betamethasone group) had SAI 3 weeks after the IACI compared to none in the control group (P > 0.9999).

What the evidence does not support

Antenatal corticosteroids probably make little or no difference to maternal death, chorioamnionitis or endometritis, and the confidence intervals leave room for harm as well as benefit. (Source 24)

• Systematic review, Moderate certainty.
• Size: 6,244 women for maternal death, 8,374 for chorioamnionitis, 6,764 for endometritis.
• Who: women given a single antenatal corticosteroid course.
• How long: index pregnancy.
• Result: maternal death RR 1.19 (95% CI 0.36-3.89); chorioamnionitis RR 0.86 (0.69-1.08); endometritis RR 1.14 (0.82-1.58); all moderate certainty, downgraded for imprecision.
• Funding: Cochrane review, independent.

The wide 95% CIs in all of these outcomes include possible benefit and possible harm.

Repeat weekly antenatal betamethasone courses produced neither benefit nor harm on neurodevelopment, growth, lung function or blood pressure in mid-childhood. (Source 7)

• Randomized trial, Moderate certainty.
• Size: 963 of 1,059 eligible long-term survivors assessed (479 repeat, 484 placebo)
• Who: children at 6 to 8 years corrected age whose mothers were at risk of very preterm birth and had already had one course.
• How long: follow-up to 6-8 years.
• Result: survival free of neurosensory disability 78.3% versus 77.3%, risk ratio 1.00 (95% CI 0.94-1.08); no differences in cognition, behaviour, body size, blood pressure, spirometry or quality of life.
• Funding: not stated in the abstract; academic randomised trial (ACTORDS follow-up)

The rate of survival free of neurosensory disability was similar in both groups (78.3% repeat versus 77.3% placebo; risk ratio 1.00, 95% confidence interval, 0.94-1.08).

Children exposed to late preterm betamethasone showed no difference in cognitive ability at a median age of 7 years. (Source 25)

• Randomized trial, Moderate certainty.
• Size: 949 children assessed (479 betamethasone, 470 placebo) of 2,831 eligible.
• Who: children aged 6 or older born to ALPS trial participants.
• How long: median age 7 years at assessment (follow-up 2017-2022)
• Result: General Conceptual Ability below 85 in 82/479 (17.1%) versus 87/470 (18.5%), adjusted RR 0.94 (95% CI 0.73-1.22); no differences in motor function, social responsiveness or behaviour; only about a third of eligible children enrolled.
• Funding: NICHD Maternal-Fetal Medicine Units Network (public funding)

a general conceptual ability score less than 85, which occurred in 82 (17.1%) of the betamethasone vs 87 (18.5%) of the placebo group (adjusted relative risk, 0.94; 95% CI, 0.73-1.22)

A programme that successfully increased antenatal corticosteroid use in six low- and middle-income countries did not reduce death among the below-5th-percentile birthweight infants (the preterm proxy group). (Source 17)

• Randomized trial, Moderate certainty.
• Size: 101 clusters, 98,137 livebirths; 4,778 infants below the 5th birthweight percentile.
• Who: rural and semi-urban clusters in Argentina, Guatemala, India, Kenya, Pakistan and Zambia.
• How long: 18 months.
• Result: antenatal corticosteroid use rose from 10% to 45% in the target group, yet 28-day neonatal mortality among below-5th-percentile infants was 225 versus 232 per 1000 livebirths, RR 0.96 (95% CI 0.87-1.06, p=0.65)
• Funding: Eunice Kennedy Shriver National Institute of Child Health and Human Development (public funding)

Among the less-than-5th-percentile infants, 28-day neonatal mortality was 225 per 1000 livebirths for the intervention group and 232 per 1000 livebirths for the control group

Where the research disagrees

Whether antenatal corticosteroids are safe to scale up in low-resource settings

• McGoldrick and colleagues, Cochrane review (2020), systematic review of 27 randomised trials, 11,272 women, GRADE high certainty for death and RDS: This evidence is robust, regardless of resource setting (high, middle or low) (Source 24)
• Althabe and colleagues, ACT cluster-randomised trial (2015), 18-month cluster-randomised trial in six countries, 101 clusters, 98,137 livebirths: Despite increased use of antenatal corticosteroids in low-birthweight infants in the intervention groups, neonatal mortality did not decrease in this group, and increased in the population overall (Source 17)

Whether antenatal corticosteroid exposure carries a long-term neurodevelopmental cost

• Raikkonen and colleagues, Finnish national cohort (2020), population-based retrospective cohort of 670,097 children with a within-sibling comparison - observational, so confounding cannot be excluded: exposure to maternal antenatal corticosteroid treatment was significantly associated with mental and behavioral disorders in children (Source 18)
• Gyamfi-Bannerman and colleagues, ALPS Follow-Up Study (2024), prospective follow-up of a randomised trial, 949 of 2,831 eligible children assessed at median age 7: administration of antenatal corticosteroids to persons at risk of late preterm delivery, originally shown to improve short-term neonatal respiratory outcomes but with an increased rate of hypoglycemia, was not associated with adverse childhood neurodevelopmental outcomes at age 6 years or older (Source 25)

How much

• Reference intake: There is no reference intake for a drug: dosing is set by the prescriber and depends completely on route and condition. As a position, the US Celestone Soluspan label states that the initial parenteral dose may vary from 0.25 to 9.0 mg per day depending on the disease being treated. (Source 12)
• Upper limit: No upper limit exists in the nutritional sense. As a position, the same label puts the usual initial parenteral range at up to 9.0 mg per day while noting that higher doses may be justified in overwhelming, acute, life-threatening situations. For the topical dipropionate products the label's limit is practical rather than numerical - a thin film once daily, twice if needed, and not under occlusive dressings. (Source 26)
• Studied: The ALPS late preterm trial gave two intramuscular injections of betamethasone 24 hours apart; the ALPS follow-up records the dose as 12 mg intramuscularly twice, 24 hours apart. (Source 25)
• Studied: The repeat-course trial used intramuscular betamethasone 11.4 mg (Celestone Chronodose) or saline placebo, repeated weekly while the risk of very preterm birth remained. (Source 7)
• Studied: The phimosis series used an 8-week course of 0.1% betamethasone-17-valerate cream. (Source 6)
• Studied: The adrenal-axis study of the two-compound product applied calcipotriene plus betamethasone dipropionate suspension once daily for 8 weeks to psoriasis covering 15 to 30% of body surface area. (Source 21)
• Studied: The knee injection study used 6 mg of betamethasone acetate/betamethasone sodium phosphate intra-articularly. (Source 5)

A common belief, and what the research shows

The belief: A steroid cream only works on the surface, so it cannot affect the rest of the body.

What the research shows: Enough gets through the skin to matter, especially with a high-potency steroid like betamethasone dipropionate over a large area or under a dressing. The label records that "Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients." In a study of a betamethasone-containing suspension on extensive psoriasis, "Two (4.7%) subjects showed signs of adrenal suppression based on the ACTH stimulation test results at week 4". In children the margin is smaller, because "Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio."

Questions and answers

What is it?

Betamethasone is a man-made corticosteroid, a modified version of the body's own cortisol. It is dispensed as different chemical forms for different routes: an injectable acetate and sodium phosphate suspension, and dipropionate or valerate creams, ointments and lotions for the skin. The topical forms are high-potency. (Source 9)

What does it do in the body?

It binds the glucocorticoid receptor inside cells and broadly switches off inflammation. Because it also reproduces cortisol's metabolic actions, large or repeated doses raise blood pressure, retain salt and water, push potassium out and increase calcium loss. Given to a pregnant woman before preterm delivery it crosses the placenta and speeds up the maturation of the baby's lungs. (Source 1)

Is it good or bad for you?

Both, depending on amount and setting - and this drug is one of the clearest examples. One antenatal course before preterm birth is high-certainty beneficial: about 2.3% fewer perinatal deaths and 4.3% less respiratory distress syndrome. The same intervention in late preterm pregnancy raised newborn low blood sugar from 15% to 24%, and a programme that pushed it out broadly in low-resource settings increased neonatal deaths overall. On the skin, repeated use of a high-potency steroid thins skin and can suppress the body's own cortisol. (Source 2)

How do you get more of it?

Betamethasone is prescription-only and has no food or dietary source. How much a person receives is chosen by the prescriber for the route and the condition. As a position, the US injection label describes an initial parenteral dose range of 0.25 to 9.0 mg per day; the topical label describes a thin film once daily, twice if needed. (Source 12)

If it is harmful, what reduces it?

For the topical forms, the documented route back is to withdraw the drug, apply it less often, or switch to a weaker steroid; adrenal function usually recovers promptly and completely after stopping, though withdrawal symptoms occasionally need systemic steroid cover. There is no antidote or clearance-accelerating treatment. (Source 15)

Why might someone be low in it or missing it?

Nobody is deficient in betamethasone - it is a drug, not a nutrient. Blood levels can be lower or higher than intended, though: strong CYP3A4 inhibitors such as ketoconazole slow its breakdown by up to 60%, and CYP3A4 inducers would be expected to do the opposite. With topical use, how much reaches the bloodstream depends on potency, surface area treated, duration and whether the skin is covered. (Source 15)

Which whole foods contain it or feed it?

No whole food contains betamethasone. Food is relevant in two ways: grapefruit inhibits the CYP3A4 enzyme that clears it, which would in theory raise exposure although no betamethasone-specific study exists, and dietary salt and potassium matter because the drug itself raises blood pressure, holds salt and water and wastes potassium. (Source 1)

What happens if you do not have it?

There is no deficiency state - someone who never takes betamethasone loses nothing. The relevant question is what happens if it is withheld where it is indicated: in the antenatal setting, the Cochrane evidence implies about 2.3 more perinatal deaths and 4.3 more cases of respiratory distress syndrome per 100 babies born preterm without a course. (Source 2)

How can you test for it?

There is no routine blood test for a betamethasone level. What is tested instead is the consequence: an ACTH (cosyntropin) stimulation test or urinary free cortisol is used to look for suppression of the body's own cortisol production, and in children growth velocity measured by stadiometry is described as a more sensitive marker of systemic steroid exposure than those hormone tests. (Source 23)

References

1. Organon LLC (US FDA label via DailyMed). CELESTONE SOLUSPAN (betamethasone acetate and betamethasone sodium phosphate) injectable suspension - US prescribing information - Clinical Pharmacology. 2026. Read the source
2. The Cochrane database of systematic reviews. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. 2020. PMID 33368142, DOI 10.1002/14651858.cd004454.pub4. Read the source
3. The New England journal of medicine. Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. 2016. PMID 26842679, DOI 10.1056/nejmoa1516783. Read the source
4. The Cochrane database of systematic reviews. Topical treatments for scalp psoriasis. 2016. PMID 26915340, DOI 10.1002/14651858.cd009687.pub2. Read the source
5. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. The effect of intra-articular injection of betamethasone acetate/betamethasone sodium phosphate at the knee joint on the hypothalamic-pituitary-adrenal axis: a case-controlled study. 2013. PMID 24013525, DOI 10.2310/jim.0b013e3182a67871. Read the source
6. Urology. Predictive power of objectivation of phimosis grade on outcomes of topical 0.1% betamethasone treatment of phimosis. 2012. PMID 22749426, DOI 10.1016/j.urology.2012.04.047. Read the source
7. Pediatrics. Mid-Childhood Outcomes of Repeat Antenatal Corticosteroids: A Randomized Controlled Trial. 2016. PMID 27650051, DOI 10.1542/peds.2016-0947. Read the source
8. Organon LLC (US FDA label via DailyMed). CELESTONE SOLUSPAN (betamethasone acetate and betamethasone sodium phosphate) injectable suspension - US prescribing information - Warnings, Serious Neurologic Adverse Reactions with Epidural Administration. 2026. Read the source
9. Organon LLC (US FDA label via DailyMed). CELESTONE SOLUSPAN (betamethasone acetate and betamethasone sodium phosphate) injectable suspension - US prescribing information - Drug Interactions, Strong CYP3A4 Inhibitors. 2026. Read the source
10. Organon LLC (US FDA label via DailyMed). CELESTONE SOLUSPAN (betamethasone acetate and betamethasone sodium phosphate) injectable suspension - US prescribing information - Drug Interactions, Amphotericin B and Potassium-Depleting Agents. 2026. Read the source
11. Organon LLC (US FDA label via DailyMed). CELESTONE SOLUSPAN (betamethasone acetate and betamethasone sodium phosphate) injectable suspension - US prescribing information - Drug Interactions, Non-steroidal Anti-inflammatory Agents. 2026. Read the source
12. Organon LLC (US FDA label via DailyMed). CELESTONE SOLUSPAN (betamethasone acetate and betamethasone sodium phosphate) injectable suspension - US prescribing information - Dosage and Administration. 2026. Read the source
13. Organon LLC (US FDA label via DailyMed). CELESTONE SOLUSPAN (betamethasone acetate and betamethasone sodium phosphate) injectable suspension - US prescribing information - Drug Interactions, Anticoagulants. 2026. Read the source
14. Organon LLC (US FDA label via DailyMed). CELESTONE SOLUSPAN (betamethasone acetate and betamethasone sodium phosphate) injectable suspension - US prescribing information - Warnings, Vaccination. 2026. Read the source
15. E. Fougera & Co. (US FDA label via DailyMed). Betamethasone Dipropionate Cream USP 0.05%, Ointment USP 0.05%, Lotion USP 0.05% - US prescribing information - Precautions, General. 2026. Read the source
16. Organon LLC (US FDA label via DailyMed). CELESTONE SOLUSPAN (betamethasone acetate and betamethasone sodium phosphate) injectable suspension - US prescribing information - Adverse Reactions, Neurologic/Psychiatric. 2026. Read the source
17. Lancet (London, England). A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries: the ACT cluster-randomised trial. 2015. PMID 25458726, DOI 10.1016/s0140-6736(14)61651-2. Read the source
18. JAMA. Associations Between Maternal Antenatal Corticosteroid Treatment and Mental and Behavioral Disorders in Children. 2020. PMID 32427304, DOI 10.1001/jama.2020.3937. Read the source
19. E. Fougera & Co. (US FDA label via DailyMed). Betamethasone Dipropionate Cream USP 0.05%, Ointment USP 0.05%, Lotion USP 0.05% - US prescribing information - Adverse Reactions. 2026. Read the source
20. E. Fougera & Co. (US FDA label via DailyMed). Betamethasone Dipropionate Cream USP 0.05%, Ointment USP 0.05%, Lotion USP 0.05% - US prescribing information - Precautions, Pediatric Use. 2026. Read the source
21. Journal of drugs in dermatology : JDD. Effect of calcipotriene plus betamethasone dipropionate topical suspension on the hypothalamic-pituitary-adrenal axis and calcium homeostasis in subjects with extensive psoriasis vulgaris: an open, non-controlled, 8-week trial. 2013. PMID 23986161. Read the source
22. Drug safety. Topical corticosteroid-induced skin atrophy: a comprehensive review. 2015. PMID 25862024, DOI 10.1007/s40264-015-0287-7. Read the source
23. Organon LLC (US FDA label via DailyMed). CELESTONE SOLUSPAN (betamethasone acetate and betamethasone sodium phosphate) injectable suspension - US prescribing information - Precautions, Effects on Growth. 2026. Read the source
24. The Cochrane database of systematic reviews. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. 2020. PMID 33368142, DOI 10.1002/14651858.cd004454.pub4. Read the source
25. JAMA. Neurodevelopmental Outcomes After Late Preterm Antenatal Corticosteroids: The ALPS Follow-Up Study. 2024. PMID 38656759, DOI 10.1001/jama.2024.4303. Read the source
26. E. Fougera & Co. (US FDA label via DailyMed). Betamethasone Dipropionate Cream USP 0.05%, Ointment USP 0.05%, Lotion USP 0.05% - US prescribing information - Dosage and Administration 2.1. 2026. Read the source